New IPO News | The IPO prospectus of Yinhang Bio on the Hong Kong Stock Exchange has expired.

Suzhou Yinhang Biotechnology Co., Ltd. (abbreviated as Yinhang Biotechnology) submitted its Hong Kong stock offering prospectus on February 12, 2026, which will expire six months later on August 12, 2026. Huatai International was its sole sponsor at the time of submission. According to the previously disclosed prospectus, Yinhang Biotechnology is a leader in synthetic biology driven by technological innovation, dedicated to providing green, sustainable, and highly efficient biobased products with significant cost advantages. In terms of active pharmaceutical ingredients and intermediates, based on data from Frost & Sullivan, after achieving large-scale production of florfenicol in 2025, the company had a market share of 24.5% during the nine months ending September 30, 2025, making it the second largest in the global florfenicol industry; for D-ethyl, based on revenue for the nine months ending September 30, 2025 (including internal and external sales), the company's market share was 44.5%, ranking first in the global D-ethyl industry.